Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Maintains Pressure Against Adulterated ED Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA says its seizure of $74,000 in mislabeled erectile dysfunction supplements from SEI Pharmaceuticals July 24 demonstrates the steps the agency will take when a company fails to heed a warning about an allegedly adulterated product

Related Content

Libimax supplement a bit too potent
Libimax supplement a bit too potent
Threat Of Adulteration For Profit Grows With Globalization Of Supply Chain
Hi-Tech Prosecution Offers FDA Model For Pursuing Bad Actors – Lawyer
Tainted ED
ED supplement crackdown
“Promising” Trend: FDA Acts On Unapproved Drugs, Tainted Supplements
FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA
CSPI Urges Recalls Of Zencore, Axcil Pending Ingredient, Ad Claims Reviews
Online Sales Of Unapproved Sex Enhancement Supplements Trouble Canada





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts